The study could lead to new therapies that prevent formation of some of the most lethal forms of the disease.
The groundbreaking process cuts carbon bonds to convert organic molecules into biologically active amine molecules.
A UCLA study shows these facilities are much less likely than others to offer the full range of core cancer services.
A UCLA Dentistry–led team has received a $5 million federal grant to develop an effective, non-addictive synthetic cannabinoid.
Immune checkpoint blockade has been ineffective for treating glioblastoma; UCLA-led research may reveal why.
The finding is from a multicenter study co-led by Dr. Antoni Ribas and a team of UCLA researchers.
A UCLA study identified an “addressable weakness” related to patient consent paperwork.
A study co-led by UCLA is the first clinical trial analyzing a targeted therapy specifically developed to treat brain tumors.
A UCLA-led study could lead to a new strategy for treating the aggressive form of brain cancer.
The inaugural chair holder is Dr. Beth Karlan, a UCLA professor of obstetrics and gynecology.
Jonsson Comprehensive Cancer Center scientists adapted advanced gene-editing technology to make their observations.
A therapeutic sponge the size of a pencil eraser boosted tumor-fighting responses in mice and kept cancer from returning.
The discovery could be a step toward improved treatment for glioblastoma multiforme.
When two drugs were delivered in one nanoparticle rather than separately, the treatment worked better in mice.
Research led by UCLA links prenatal exposure to specific chemicals to higher rates of eye cancer.
A new study in mice suggests that adding iNKT cells to a stem cell transplant could reduce complication severity.
The study could eventually lead to more treatment options for leukemia, sickle cell disease and other conditions.
The oral medication, ERAS-801, targets a rogue gene found in about 60% of people with the aggressive form of brain cancer.
The findings could improve doctors’ ability to offer truly personalized cancer therapy.
A UCLA study suggests that new small-molecule drugs that inhibit a protein called ATR could be used in combination with interferon “amplification.”
The veteran firefighter, who expects to earn his Ph.D. in chemistry in winter quarter, is using his knowledge to improve the health and safety of his colleagues.
Using stem cell engineering and organoid technology, UCLA researchers were able to produce large quantities of powerful cancer-fighting iNKT cells.
A team led by UCLA scientists found that removing IGF2BP3 selectively targets cancer cells while leaving healthy cells alone.
UCLA researchers discover that MAOIs could activate immune system to shrink various types of tumors.
The research, conducted on mice, targets a newly discovered molecular “checkpoint” that enables cancer stem cells to evade the immune system.